NCT00175513

Brief Summary

This is an 18 week (2 weeks run-in, 16 weeks double blind) trial, to determine if an antiviral drug, valacyclovir (Valtrex) is helpful in treating the symptoms of psychosis, a form of a mental disorder.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Sep 2005

Typical duration for phase_2

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2005

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

September 11, 2005

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 15, 2005

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2009

Completed
Last Updated

April 14, 2011

Status Verified

April 1, 2011

Enrollment Period

4 years

First QC Date

September 11, 2005

Last Update Submit

April 12, 2011

Conditions

Psychosis

Keywords

Psychosisearly psychosisfirst episode psychosisschizophreniaschizoaffectiveschizophreniformbipolar disordervaltrexvalacyclovir.

Interventions

Valacyclovir (Valtrex)DRUG

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects antipsychotic, mood stabilizing and antidepressant drug treatment must have been stable for at least 3 months, and there is no plan to change the drug treatment during the 4-month phase of the study.
  • Subjects must be seropositive for HSV-1, HSV-2 and/or CMV.
  • Subjects must achieve a level of understanding and expressive capacity sufficient to communicate adequately with the study coordinator and to participate in cognitive testing.
  • Subjects must be able to provide written informed consent.

You may not qualify if:

  • Females of childbearing age will agree not to become pregnant and will agree to use a medically acceptable method of birth control.
  • Inability to participate in cognitive testing due to severe persistent psychosis or other condition.
  • Mental handicap.
  • Subjects with known hypersensitivity or allergy to valacyclovir or acyclovir.
  • Patient taking nontopical antiviral medications with anti-herpes activity on a regular basis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Eric Martin Pavilion

Victoria, British Columbia, Canada

Location

Peace Arch Hospital

White Rock, British Columbia, Canada

Location

MeSH Terms

Conditions

Psychotic DisordersSchizophreniaBipolar Disorder

Interventions

Valacyclovir

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental DisordersBipolar and Related DisordersMood Disorders

Intervention Hierarchy (Ancestors)

AcyclovirGuanineHypoxanthinesPurinonesPurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • William Honer, MD

    University of British Columbia

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 11, 2005

First Posted

September 15, 2005

Study Start

September 1, 2005

Primary Completion

September 1, 2009

Study Completion

September 1, 2009

Last Updated

April 14, 2011

Record last verified: 2011-04

Locations

CA(2)